Three Eastside tech firms have pioneered lifesaving new devices and treatments in the past year. Redmond’s Mobisante has created a MOBILE ULTRASOUND IMAGING DEVICE—the MobiUS SP1 ultrasound system—that is the first smartphone-based diagnostic device to be cleared by the FDA. The device, released last October, fits into a pocket and can be charged anywhere, making it ideal for disaster relief organizations. It is also affordable and easy to use, reducing the time required to diagnose and treat patients, as does Physio-Control, Inc.’s new portable, dedicated ELECTROCARDIOGRAM DEVICE for basic-life support teams. Launched by the Redmond company last August, the ReadyLink 12-Lead ECG device is a small, lightweight tool that can acquire and transmit a patient’s ECG to hospital teams via cloud-based data technology. Also in August, Bothell company Seattle Genetics, Inc. earned FDA approval for the first in a new class of CANCER DRUGS. Adcetris is designed to target and kill cancer cells in patients with Hodgkin’s lymphoma (HL)—the first new drug approved by the FDA for HL in more than 30 years.